NEWS HIGHLIGHTSMedia Articles Related to Aloprim (Allopurinol)
ACR: Allopurinol Sensitivity More Likely in Patients with Renal Problems (CME/CE)
Source: MedPage Today Rheumatology [2009.10.28]
PHILADELPHIA (MedPage Today) -- Hypersensitivity to the anti-uricemic drug allopurinol, often leading to acute kidney failure, is up to three times as common in patients who already suffer renal impairment, according to research presented here.
ACR: Pump Up the Allopurinol to Prevent Gout (CME/CE)
Source: MedPage Today Rheumatology [2009.10.23]
PHILADELPHIA (MedPage Today) -- Going beyond the recommended dosing of allopurinol (Zyloprim) to treat patients with gout may help prevent recurrence safely, researchers contended here.
ASN: Febuxostat Works in Gout Patients with Renal Impairment (CME/CE)
Source: MedPage Today Rheumatology [2009.11.02]
SAN DIEGO (MedPage Today) -- In patients with gout and preexisting mild to moderate renal impairment, febuxostat (Uloric) is more effective and as safe as allopurinol, the gold standard gout treatment, researchers found.
Published Studies Related to Aloprim (Allopurinol)
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. [2009.07.29]
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositisTo prepare and evaluate an allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis, 33 patients with malignant disorders, who were going to receive 5-fluorouracil containing chemotherapy, were enrolled in a placebo-controlled double-blinded randomized clinical trial...
Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. [2009.07]
BACKGROUND: Fetal hypoxia is an important determinant of neonatal encephalopathy caused by birth asphyxia, in which hypoxia-induced free radical formation plays an important role. HYPOTHESIS: Maternal treatment with allopurinol, will cross the placenta during fetal hypoxia (primary outcome) and reduce S-100B and free radical formation (secondary outcome)... CONCLUSIONS: Maternal allopurinol/oxypurinol crosses the placenta during fetal hypoxia. In fetuses/newborns with therapeutic allopurinol/oxypurinol concentrations in cord blood, lower plasma levels of the brain injury marker protein S-100B were detected. A larger allopurinol trial in compromised fetuses at term seems warranted. The allopurinol dosage must be adjusted to achieve therapeutic fetal allopurinol/oxypurinol concentrations.
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. [2009.06]
OBJECTIVES: To compare the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day used to attain a target serum urate concentration (sUr) < or =0.30 mmol/l (5 mg/dl)... CONCLUSIONS: Increasing the allopurinol dose from 300 to 600 mg/day and the benzbromarone dose from 100 to 200 mg/day according to the target sUr produced significantly higher success rates (both 78% successful in attaining sUr < or =0.30 mmol/l). No significant differences in treatment success between benzbromarone and allopurinol were found after dose escalation. Trial registration number: ISRCTN49563848).
Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography. [2009.04.07]
AIM: To assess the efficacy of allopurinol to prevent hyperamylasemia and pancreatitis after endoscopic retrograde cholangiopancreatography (PEP)... CONCLUSION: Oral allopurinol before ERCP decreased the incidences of hyperamylasemia and pancreatitis in patients submitted to high-risk procedures.
A double-blind trial of adjunctive allopurinol for schizophrenia. [2009.04]
CONCLUSIONS: Allopurinol may be an effective adjunctive medication for some patients with persistent schizophrenia.
Clinical Trials Related to Aloprim (Allopurinol)
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil [Completed]
OBJECTIVE:
Compare the efficacy and side effects of allopurinol versus glucantime versus
allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as Add-on Antipsychotics in Patients With Schizophrenia [Not yet recruiting]
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo,
as add-on to anti-psychotics in the treatment of patients with schizophrenia.
Study of Rasburicase Versus Allopurinol in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome [Active, not recruiting]
This is a randomized, multi-center, open-label, parallel group study with three arms:
- rasburicase alone,
- rasburicase followed by allopurinol, and
- allopurinol alone
The primary objective is to compare the adequacy of control of plasma uric acid concentration
and the safety profile among the three arms.
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. [Completed]
A Study comparing febuxostat, allopurinol and placebo in subjects with gout.
APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X [Recruiting]
Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal
coronary arteriograms) is high with continuing episodes of chest pain and frequent hospital
readmissions. Management of this syndrome represents a major challenge to the treating
physician. Evidence for the important role of endothelial dysfunction and oxidative stress
in the pathogenesis of cardiac syndrome X has been recently strengthened by the finding that
basal superoxide production predicts future cardiovascular events in this patient group. The
investigators have recently shown that high-dose allopurinol abolishes vascular oxidative
stress and improves endothelial function in patients with chronic heart failure, which makes
allopurinol a prime candidate to reduce oxidative stress in syndrome X. The hypothesis to be
tested in this study is whether allopurinol offers dual benefits of improving vascular
function and reducing myocardial ischaemia in patients with cardiac syndrome X. This study
may discover a novel way to improve endothelial function and anginal symptoms which are
often debilitating in these patients.
|
